NCT03494179已完成1 期
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 31
- 主要终点
- overall response rate (ORR)
研究概览
简要总结
The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.
详细描述
Part I: PK/PD and safety evaluation -Two regimens of ICP-022 (High dose QD and low dose BID) were designed for assessment of safety, as well as PK/PD profiles. The recommended dose of phase II clinical study will be determined according to the Part I results.
Part II: Dose expansion -Anti-tumor effects of ICP-022 in Chinese patients with R/R MCL will be evaluated in approximately 80 subjects. The recommended Phase 2 dose will be used in the Part II.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women between 18 and 75 years old
- •Histologically confirmed mantle cell lymphoma (MCL), with either t(11;14) by cytogenetics and/or cyclin D1 overexpression by immunohistochemistry (IHC)
- •Subjects with refractory or relapsed mantle cell lymphoma who has received at least 1 but no more than 4 prior therapies for MCL
- •At least one measurable tumor of greater than 1.5 centimeter in long axis by contrast-enhanced CT/MRI
- •ECOG performance status of 0-2
- •Documented failure to achieve at least partial response (PR) or documented disease progression after response to, the most recent treatment regimen.
- •Subjects who meet the following laboratory parameters:
- •Absolute neutrophil count (ANC) ≥ 1.5×109/L Platelet count ≥ 75×109/L, independent of growth factor support within 7 days of the first dose with study drug, Hemoglobin ≥ 80 g/L; ANC ≥ 1.0×109/L, Platelet count ≥ 50×109/L if bone marrow involvement
- •Total bilirubin ≤ 2× ULN; AST or ALT ≤ 2.5 ULN; Creatinine clearance ≥ 30ml/min; Amylase ≤ ULN and Lipase ≤ ULN
- •International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin time (APTT) ≤ 1.5 ULN
- •Life expectancy ≥ 4 months
- •Able to provide signed written informed consent
排除标准
- •History of other active malignancies within 5 years of study entry, unless cured without evidence of relapse or metastasis
- •Current or history of lymphoma involved central nervous system
- •Prior corticosteroids (at dosages equivalent to prednisone > 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, radiation therapy, or antibody based therapies or anti-cancer TCM within 4 weeks of the start of study drug.
- •Non-hematological toxicity must recover to ≤ Grade 1 from prior anti-cancer therapy
- •Current clinically significant cardiovascular disease including:
- •Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%
- •Primary cardiomyopathy
- •Clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male)
- •Uncontrolled hypertension
- •Known active bleeding within 2 months of screening or currently taking anticoagulant/antiplatelet drugs
- •Urine protein ≥ 2+ and quantitation ≥ 2g/24hours
- •History of deep vein thrombosis or pulmonary embolism
- •Disease significantly affecting gastrointestinal function such as dysphagia, chronic diarrhea, intestinal obstruction, or resection of the stomach
- •Allogeneic stem cell transplant within 6 months prior to first dose of study drug or related active infection
- •Major surgery within 6 weeks of screening, except for diagnostic test or vascular access setup
- •Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection
- •Any history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe lung function impairment
- •Prior exposure to a BTK inhibitor，BCR pathway ingibitor(such as PI3K, SYK) or BCL-2 kinase inhibitor
- •Suitable and ready for allogeneic stem cell transplant
- •Inability to comply with study procedures
- •Drug abuser or alcoholics
- •Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children
- •Requires treatment with moderate or strong cytochrome P450 family 3, subfamily A (CYP3A) inhibitors or strong CYP3A inducers.
研究组 & 干预措施
Low Dose of ICP-022
Experimental
Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
干预措施: ICP-022 (Drug)
High Dose of ICP-022
Experimental
Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
干预措施: ICP-022 (Drug)
结局指标
主要结局
overall response rate (ORR)
时间窗: Up to 3 years
The efficacy measured by overall response rate (ORR) in Part II according to the 2014 International Working Group NHL
次要结局
- Area under the concentration time curve up to the last data point above LOQ (AUC(last))(up to 4 weeks)
- Area under the concentration time curve up to the time "t" (AUC(0-t))(up to 4 weeks)
- overall survival (OS)(Up to 3 years)
- The percent of target occupancy(up to 4 weeks)
- Occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria in Part I(Up to 3 years)
- Maximum plasma drug concentrations (Cmax)(up to 4 weeks)
- time to progression (TTP)(Up to 3 years)
- progression free survival (PFS)(Up to 3 years)
- Time of maximum plasma drug concentrations (Tmax)(up to 4 weeks)
- Apparent half-life for designated elimination phases (t½)(up to 4 weeks)
研究者
研究点 (31)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)MZLNCT03797456Beijing InnoCare Pharma Tech Co., Ltd.111
撤回
不适用
Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. AeruginosaCystic FibrosisNCT01090908Aradigm Corporation
撤回
1 期
NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung DiseaseLung DiseasePulmonary DiseaseAlpha-1 Antitrypsin Deficiency-associated Lung DiseaseAATDAlpha-1 Antitrypsin DeficiencyNCT06622668Intellia Therapeutics30
已完成
1 期
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin LymphomaRelapsed or Refractory Classical Hodgkin LymphomaNCT05216835AstraZeneca45
招募中
1 期
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid TumorsAdvanced Solid TumorCervical CancerNCT06223308Shanghai Huaota Biopharmaceutical Co., Ltd.54